Table 3.
| ||||||
---|---|---|---|---|---|---|
entry | substrate | catalyst | ⊢e.r.c⊣ | d.r.d (trans:cis) | conv.b (%) | |
trans-7 | cis-7 | |||||
1 | 4a | 9 | - | - | 61:39 | 52 |
2 | P32 | 76:24 | 91:9 | 38:62 | 65 | |
| ||||||
3 | 4b | 9 | - | - | 62:38 | 65 |
4 | P32 | 68:32 | 82:18 | 51:49 | 52 | |
5 | 4c | 9 | - | - | 56:44 | 38 |
6 | P32 | 61:39 | 86:14 | 35:65 | 59 | |
7 | 4d | 9 | - | - | 68:32e | 73 |
8 | P32 | 72:28 | 89:11 | 49:51e | 40 |
Reported results are the average of at minimum two trials,
Conversion to product (conv.) was determined by UPLC/MS.
Enantiomeric ratios (e.r.) were determined by HPLC.
Diastereomeric ratio (dr) was determined by UPLC/MS.
Dr was determined by HPLC.